Schizophrenia

National class action approved for users of this antipsychotic drug

by

The companies behind a prescription drug that was recently approved to treat symptoms of agitation in Alzheimer’s patients are facing a class-action lawsuit over alleged “harmful side effects” to patients. The lawsuit relates to the antipsychotic drug Rexulti, which was approved by Health Canada in January for managing agitation associated with dementia due to Alzheimer’s … Read more

Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio

by

NEW YORK — Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal. Bristol Myers Squibb and Karuna announced their merger agreement on Friday. The transaction, which amounts to $330 per share in cash, offers a premium of 53% over Karuna’s stock on … Read more